CD19 and B-cell non-Hodgkin lymphoma: A total of 68 consecutive patients (mean age 55.2±14 years, 20 females) affected by refractory/relapsed B-cell non-Hodgkin lymphoma underwent anti-CD19 CAR T-cell therapy from September 2019 to September 2022 and were included in the study.